PA 401

Drug Profile

PA 401

Alternative Names: Glycafilin; PA-04-001; PA-401; Recombinant human CXCL8 mutant

Latest Information Update: 04 Sep 2013

Price : $50

At a glance

  • Originator ProtAffin Biotechnologie
  • Class Anti-inflammatories; Antibronchitics; Proteins
  • Mechanism of Action Glycosaminoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Chronic obstructive pulmonary disease; Cystic fibrosis; Delayed graft function; Pneumonia; Reperfusion injury; Rheumatoid arthritis

Most Recent Events

  • 31 Jul 2013 Discontinued - Preclinical for Pneumonia in Austria (Parenteral)
  • 31 Jul 2013 Discontinued - Phase-I for Delayed graft function in United Kingdom (Parenteral)
  • 31 Jul 2013 Discontinued - Phase-I for Cystic fibrosis in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top